Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms by M. Nizzardo et al.
ANNALS OF NEUROSCIENCES VOLUME 18 NUMBER 4 OCTOBER 2011 www.annalsofneurosciences.org
156
ANNALS
JOURNAL CLUB
Experimental Neurology 2011; 229: 214–225
Beta-lactam antibiotic offers neuroprotection in a spinal muscular 
atrophy model by multiple mechanisms
Monica Nizzardo,a Martina Nardini,a Dario Ronchi,a Sabrina Salani,a Chiara Donadoni,a Francesco 
Fortunato,a Giorgia Colciago,a Marianna Falcone,a Chiara Simone,a Giulietta Riboldi,a Alessandra 
Govoni,a Nereo Bresolin,a,b,c Giacomo P. Comi,a,b Stefania Corti,a,b,*
aDino Ferrari Centre, Department of Neurological Sciences, University of Milan, IRCCS Foundation Ca’ Granda, Ospedale Maggiore Policli-
nico, Milan, Italy, bCentre of Excellence on Neurodegenerative Diseases, University of Milan, Italy, cIRCCS Eugenio Medea, Bosisio Parini, 
Lecco, Caps
Correspondence : Stefania Corti, Department of Neurological Sciences, University of Milan, IRCCS Foundation Ca’ Granda, Ospedale Maggiore Policlinico,  
Padiglione Ponti, Via Francesco Sforza 35, 20122 Milan, Italy, E-mail: stefania.corti@unimi.it
Sonu Bhatia
Department of Biotechnology, Panjab University, Chandigarh, INDIA
Histological analysis of muscles of hind limbs for total tibialis 
anterior (TA), cross sectional area, total TA myofiber number 
and myofiber diameter was performed by the author. Spinal 
cord sections were subjected to immunohistochemistry using 
monoclonal antibodies against motoneuron specific mark-
ers SMI 32 antigen followed by secondary antibody AlexFlour 
488. Purified RNA isolated from spinal cord followed by cRNA 
preparation and oligonucleotide microarray hybridization. Bi-
otinylated cRNA was hybridized to Affymetrix GeneChip Mouse 
Genome 430A 2.0 array at 47oC overnight and visualized on 
GeneArray 2500 Scanner. RNA from four groups of selected 
animals was reverse transcribed on Real time PCR system. Spi-
nal cord protein was extracted from experimental animals and 
subjected to semi quantitative western blot. The membranes 
were probed with mouse anti SMN, anti EAAT2 antibody, rab-
bit anti BAX, anti PRG2, anti TDP 43, anti FUS and anti actin 
antibodies followed by use of secondary antibodies and chemi-
luminescence detection techniques. The staining sections and 
proteins density were measured with NIH Image software. Ka-
plan Meier analysis was used on lifespan using log rank post 
hoc test. ANOVA and Tukey-post hoc analysis of growth curve 
was performed. Student’s test was used for statistical analysis 
and upper significance level of 0.05 was used.
Implications
This study showed the neuroprotective effect of ceftriaxone 
on motoneurons and motor unit integrity by modification of 
gene expressions. The treatment of SMA mice with ceftriax-
one increased survival time by 31.6%, slightly changed SMN 
defect mediated pathology and ameliorated motor dysfunc-
tion. A number of unregulated genes containing one or more 
NF-κB binding sites were observed after treatment. The au-
thor reported both GLT1 mediated reduction of excitotoxicity 
and activation of NRF2 related factors which may contribute 
to phenotypic amelioration. Out of several genes involved in 
transcription and RNA processing few of them including FUS, 
plastin 3 got down-regulated in SMN. These can be used as 
biomarkers to correlate with disease progression, however rel-
Background
Spinal muscular atrophy (SMA) is the most common genetic 
neurodegenerative disease leading to death in childhood.1 SMA 
is characterized by the loss of spinal cord anterior horn neurons 
and progressive denervation of skeletal muscles. SMA is caused 
by deletion or mutation of the telomeric copy of human surviv-
al motor neuron gene 1 (hSMN1) and retention of the hSMN2 
gene.2,3 SMA animal models are extremely useful in studying 
the mechanism of SMA-related motoneuronal death, and may 
provide an in vivo system for testing a potential SMA therapy. 
In mice there is one survival motor neuron gene which is equiv-
alent to SMN1. Complete loss of this gene results in embryonic 
lethality, due to the essential role of SMN in the assembly of 
small nuclear ribonucleoproteins (snRNPs).4,5 SMN2 can pro-
duce the functional SMN protein required for all cells, including 
motoneurons. Expression of SMN lacking exon 7 (SMNΔ7) un-
der the SMN promoter in severe SMA mice modulates the phe-
notype: on average, the mice live for two weeks.6 Earlier works 
reported that, ceftriaxone, a β-lactam antibiotic slows the loss 
of muscle strength and extend survival in amyotrophic lateral 
sclerosis (ALS) in mice. Ceftriaxone prevents motoneuron loss 
in a dose-dependent manner. This effect may be linked due to 
improvement of glutamate clearance in spinal cord explants as 
expression of excitatory amino acid transporter-2 is increased. 
Indeed, ceftriaxone is neuroprotective in vitro.7 Based on the 
above observation Nizzardo et al proposed this study to test 
the therapeutic effect of ceftriaxone in SMA.
Study Design
To study of effect of β-lactam antibiotic as neuroprotectant and 
the possible mechanism, in spinal muscular atrophy, the au-
thors used a triple mutant SMA mouse. This animal model was 
genotyped using PCR based assay and carries two transgenic 
alleles and a single targeted mutant. Ceftriaxone was given via 
intraperitoneal injection against suitable control and analysis 
was done daily for clinical signs of the disease. Righting re-
flex and Hind limb suspension test were performed to analyze 
improvement for neuromuscular function of diseased mice. 
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evance of these genes to disease in humans and efficacy of 
other drugs need to be studied.
doi : 10.5214/ans.0972.7531.1118407
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